Keyphrases
Rheumatoid Arthritis
81%
Denmark
80%
National Cohort Study
68%
Psoriatic Arthritis
54%
TNF Inhibitors
32%
Hazard Ratio
29%
COVID-19 Hospitalization
29%
Arthritis Patients
28%
Incidence Rate
28%
Health Registries
21%
Register Study
21%
Rheumatoid Arthritis Patients
20%
COVID-19
19%
Polyautoimmunity
19%
Cutaneous Lupus Erythematosus
19%
Systemic Lupus Erythematosus
19%
COVID-19 Incidence
19%
Inflammatory Rheumatic Diseases
19%
Joint Surgery
19%
Joint Replacement
16%
Hospitalization Risk
15%
Disease-modifying Antirheumatic Drugs (DMARDs)
15%
Comorbidity
15%
Nationwide Registers
14%
Standardized Incidence Ratio
14%
Biologic Disease-modifying Antirheumatic Drugs
13%
Tumour Necrosis Factor Inhibitor (TNFi)
13%
Nested Case-control Study
11%
Matched Cohort Study
11%
Autoimmune Disease
11%
Danish National Patient Registry
10%
Sweden
10%
Lymphoma
10%
Rheumatology
10%
Solid Cancer
9%
Secular Trends
9%
Biological Treatment
9%
Medical Complications
9%
Time Trends
9%
Total Hip or Knee Arthroplasty
9%
Respiratory Failure
9%
Population-based Cohort Study
9%
Treatment Outcome
9%
Methotrexate
9%
Novel Immunomodulators
9%
Gender Differences
9%
Age-matched
9%
Gout
9%
Biologic Immunomodulators
9%
Incidence Trends
9%
Medicine and Dentistry
Cohort Analysis
79%
Rheumatoid Arthritis
71%
Psoriatic Arthritis
42%
TNF Inhibitor
33%
Biological Product
30%
Population
28%
Malignant Neoplasm
23%
Disease-Modifying Antirheumatic Drug
23%
Infection
21%
Health Care
19%
Operation on Joint
19%
COVID-19
19%
Arthritis
19%
Joint Replacement
16%
Disease
15%
Rheumatology
14%
Disease Modifying Antirheumatic Drug
14%
Drug Therapy
13%
Severe Acute Respiratory Syndrome Coronavirus 2
12%
Odds Ratio
11%
Standardized Incidence Ratio
11%
Hazard Ratio
11%
Rheumatic Disease
10%
Non-Hodgkin Lymphoma
9%
Proportional Hazards Model
9%
Sex Difference
9%
Upper Limb
9%
Cancer Risk
9%
Interstitial Lung Disease
9%
Prevalence
9%
Immunomodulating Agent
9%
Subacute Cutaneous Lupus Erythematosus
9%
Knee Arthroplasty
9%
Spondylarthritis
9%
Gout
9%
Methotrexate
9%
Chronic Pain
9%
Glucocorticoid
9%
Hip Arthroplasty
9%
Premature Mortality
9%
Psoriasis
9%
Time Series Analysis
9%
Systemic Lupus Erythematosus
9%
Respiratory Failure
9%
Case-Control Study
9%
Mortality
9%
Cohort Effect
9%
Growth
9%
Logistic Regression Analysis
6%
Diabetes Mellitus
6%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
100%
Rheumatoid Arthritis
52%
Psoriatic Arthritis
34%
Infection
28%
Biological Product
27%
Tumor Necrosis Factor Inhibitor
26%
Rheumatic Disease
20%
Skin Lupus Erythematosus
19%
Systemic Lupus Erythematosus
19%
Malignant Neoplasm
19%
SARS Coronavirus
14%
Disease
12%
Spondylarthritis
11%
Vaccination Policy
10%
Interstitial Lung Disease
9%
Disease Modifying Antirheumatic Drug
9%
Pharmacotherapy
9%
Methotrexate
9%
Immunomodulating Agent
9%
Arthritis
9%
Respiratory Failure
9%
Psoriasis
9%
Nonhodgkin Lymphoma
9%
Autoimmune Disease
8%
Standardized Incidence Ratio
7%
Lupus Erythematosus
7%
Comorbidity
6%